Results 71 to 80 of about 1,268 (176)

Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA

Neurology and Therapy
Introduction Oral corticosteroids (OCSs) and nonsteroidal immunosuppressant therapies (NSISTs) remain widely used for the clinical management of patients with generalized myasthenia gravis (gMG), despite well-documented risks.
Francesco Saccà, Justin Lee, Karen S. Yee, Nicholas J. Silvestri, Guido Sabatella   +4 more
doaj   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Efgartigimod Followed by Telitacicept in Adult Generalized Myasthenia Gravis: A Retrospective Case Series [PDF]

Yuan Zhang,1,* Zheyu Fang,1,* Yaping Liu,2,* Bingbing Wan,1 Qiaoyi Zhang,1 Xi Qu,1 Shengli Pan,1 Yu Zhang,1 Yilin Dai,1 Shiyin Yang,1 Jia Li,1 Xu Zhang1 1Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University ...
Liu Y, Wan B, Fang Z, Li J, Pan S, Zhang Y, Zhang X, Qu X, Yang S, Zhang Q, Dai Y   +10 more
core   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology
Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG).
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
doaj   +1 more source

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database

Frontiers in Pharmacology
ObjectiveEfgartigimod alfa, approved for treating generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, has uncertain long-term safety in large populations This study analyzed adverse events ...
Yunlin Yang, Jinfeng Liu, Wei Wei, Wei Wei, Wei Wei   +4 more
doaj   +1 more source

Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain–Barré syndrome

Orphanet Journal of Rare Diseases
Objective This study aimed to compare the effectiveness of intravenous efgartigimod and intravenous immunoglobulin (IVIg) in patients with Guillain–Barré syndrome (GBS).
Huiqiu Zhang, Feipeng Zhai, Menghan Su, Yi Zhang, Jing Ma, Junsen Zhao, Juan Wang, Xueli Chang, Yi Liu, Junhong Guo, Wei Zhang   +10 more
doaj   +1 more source

Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study [PDF]

Background: China has a large number of myasthenia gravis (MG) patients, creating an urgent need for rapid and tolerable treatment options. As the first-approved Fc receptor antagonist, efgartigimod has bright prospects for treating MG.
Geke Zhu, Wanying Wang, Xiangtao Nie, Wenjing Qi, Xiuming Guo, Han Zhou, Lei Hao, Yongbo Ma   +7 more
core   +1 more source

The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis [PDF]

Background Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, where autoreactive immunoglobulin G (IgG) plays a key role in disease pathogenesis.
Xin-Wei Wang, Yun Wang, Jia-Jun Cheng, Fu-Qiang Wang, Zhang-Yi Dai   +4 more
core   +1 more source

Efgartigimod Alfa-fcab

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis [PDF]

Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or
Anne Sumbul, Elena Cortés‐Vicente, Shahram Attarian, Daniela Hristova, Gregory Sahagian, Yessar Hussain, Kristl G. Claeys, Rosa H. Jimenez, Kelly Gwathmey, Edward Brauer, Renato Mantegazza, Vera Bril, Delphine Masschaele, the ADAPT NXT Study Group, Andreas Meisel, Ali A. Habib, Deborah Gelinas   +16 more
core   +1 more source